Dr Reddy's Set For Quality Revamp Amid FDA Warning
This article was originally published in Scrip
Executive Summary
Days after investors battered the company's stock following a surprise three-plant FDA warning letter, Dr Reddy's Laboratories' CEO, GV Prasad, has emphasised that a "revamp" of the firm's quality systems and processes is a top organizational priority.